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Despite few studies conducted in non-mammalian species, there has been a number of reports pertaining to the occurrence 
of a natriuretic-like substance in lower organisms. Thus, an immunoreactive substance reacting with antibodies directed 
against mammalian atria1 natriuretic factor has previously been detected both in heart atria and ventricles of a chordate, 
the frog. This substance was isolated and purified from frog heart atria and its amino acid sequence established. The 
sequence, Ala-Pro-Arg-Ser-Ser-Asp-Cys-Phe-Gly-Ser-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gl~Met-Gly-Cys-Gly-Arg- 
(Phe), is highly homologous to known mammalian ANF sequences. However, when aligned with the complete mamma- 
lian ANF precursor sequence at positions 121 to 151, it exhibits a single amino acid insertion at position 129 and other 
substitutions at positions 121, 125, 133, 135, 144, 147 and 148. Some evidence is also presented concerning the occurrence 
of uncleaved frog pronatriodilatin, the precursor form of ANF. This study represents the first report pertaining to the 
structure of a non-mammalian ANF and its precursor. 
Atria1 natriuretic factor; Amphibian atrium; Peptide evolution; Amino acid sequence; (Frog) 
1. INTRODUCTION 
In recent years, atria1 natriuretic factor (ANF) 
or atriopeptin (ANP) has been shown to be a po- 
tent, diuretic, natriuretic and vasorelaxant peptide. 
Since its biological action has been reported upon 
injection of heart atria extract [l], numerous 
studies have been conducted on its localization, its 
biological properties and its structure (reviewed in 
[2]). Thus, in mammals, its major but not exclusive 
site of synthesis and secretion has been shown to be 
heart cardiocytes. Recently, the widespread occur- 
rence of ANF and ANF-like peptide in a variety of 
other tissues have stirred considerable interest 
since these new locations could be in favor of other 
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biological activities apart from those already 
documented. Furthermore, its highly conserved 
primary structure, in particular with respect to its 
intramolecular disulfide bridge, has been ex- 
emplified in a great number of species albeit all 
belonging to the same phylum. Thus, the amino 
acid sequence of ANF and sometimes, also, of its 
precursor termed pro-ANF or pronatriodilatin, is 
known for rat, human, bovine, porcine, dog and 
rabbit [2]. Furthermore, the structure of rat, 
human, mouse and bovine genes are all known 
thus confirming yet again that not only are the 
amino acid sequences extremely homologous but 
also the structural organization of the genes. 
Even though there have been reports pertaining 
to the presence of a peptide akin to mammalian 
ANF in lower species, no structural data are as yet 
available. Nevertheless, ANF-like substances have 
been detected in the hearts of various species most- 
ly through the use of immunological methods such 
300 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/88/$3.50 0 1988 Federation of European Biochemical Societies 
Volume 238, number 2 FEBS LETTERS October 1988 
as radioimmunoassays and immunocytochemistry. 
Chromatographic behavior, electron microscopy 
and bioassays, general methods relying on a priori 
mammalian ANF properties, were also used. Thus, 
antibodies directed against the ANF bioactive core 
(position 101-126 of pro-ANF) were able to pro- 
duce a positive reaction in the atria of toad, frog, 
snake, hen and fish [3]; this study thereby confirm- 
ed results previously obtained by DeBold and 
Salerno [4] in frog hearts. Similar results were 
described by Reinecke et al. [5] which confirmed 
that cardiac hormones are not confined to mam- 
mals but can be found in avian, reptiles, amphi- 
bian and bony fishes. More precisely, ANF-like 
peptides together with the precursor forms were 
described in both frog atria [6] and, interestingly 
albeit at a much reduced level, in ventricles [7]. 
Finally, the heart atria and ventricles as well as 
cerebral and esophageal ganglia of a snail (Helix 
pomatia) [8], the hemolymph as well as numerous 
organs including ganglia of a marine snail (Aplysia 
californica) [9], and the eyestalks of a crustacean 
(Homarus gammarus) [lo] were all recently shown 
to contain ANF-like immunoreactivities. In these 
species, it is largely recognized that such entities 
belong to the neuroendocrine system ‘where, in ad- 
dition to a purely endocrine function, they might 
play a role as neurotransmitter or neuro- 
modulator. The recent demonstration that, in 
mammals, ANF is largely distributed at various 
locations in the central nervous system (CNS) and 
that, in addition, it exists in brain, at least in por- 
cine, in two molecular forms, ANF and brain 
natriuretic peptide (BNP) [ll], can be taken as 
evidence in favor of such a dual role. 
In the present study, we report the purification 
and chemical characterization of ANF from acid 
extracts of frog (Rana ridibunda) heart atria. This 
represents the first report concerning the primary 
structure of this biologically important peptide and 
its precursor in a non-mammalian species and thus 
confirms results obtained by immunological 
methods. 
2. MATERIALS AND METHODS 
2.1. Peptide extraction and crude purification 
Deep frozen frog heart atrias (49 g, from Mont Saint- 
Aignan, France) were homogenized using a Polytron in 500 ml 
of 1 M acetic acid containing 1 mM EDTA and the homogenate 
was centrifuged at 40000 x g for 30 min. The resulting superna- 
tant was directly applied for a SP-Sephadex-C25 column (1.5 x 
12 cm) at a flow rate of 2.5 ml/min. After application of the 
sample, the column was washed successively with (i) 40 ml of 
1 M acetic acid, (ii) 40 ml of 150 mM ammonium acetate buf- 
fer, pH 6.0, (iii) 40 ml of 150 mM ammonium acetate buffer, 
pH 7.4, and (iv) finally, the retained material was eluted with 
1.5 M ammonium acetate buffer, pH 7.4. The pH of the eluate 
was immediately adjusted to 4-5 by addition of 2.5 ml of 
glacial acetic acid and 150 pl of trifluoroacetic acid (TFA). 
The acidified fraction was then loaded onto apBondapak-Crs 
semi-preparative column (1 x 15 cm) connected to a Waters 600 
liquid chromatographic system using a flow rate of 5 ml/min. 
The elution was performed using a linear gradient (lo-70%) of 
acetonitrile containing 0.1% TFA at a flow rate of 5 ml/min 
over a period of 120 min. The eluted fractions were monitored 
by measuring absorbance at 280 nm. The ANF-containing frac- 
tions identified by radioimmunoassay (RIA) and radioreceptor 
assay (RRA) were pooled and labeled fraction A, B and C 
following their order of elution from the column. Fractions A 
and C were further purified by HPLC. 
2.2. Purification of ANFfraction A 
Fraction A was further purified on a Vydac-Crs column 
(0.46 x 25 cm) in three steps using various gradients or ion- 
pairing agents. 
It was first eluted from the column using a linear gradient 
(13.5-40.5%) of acetonitrile containing 0.1% TFA using a flow 
rate of 1 ml/min over 60 min. The ANF-immunoreactive peak 
A was resolved into two peaks eluting at 22% and 23.4% 
acetonitrile denoted Al and A2, respectively. Fraction Al was 
rechromatographed using a linear gradient (18-45%) of 
acetonitrile and 0.05% heptafluorobutyric acid (HFBA) at 
1 ml/min for 60 min. During this step, Al was separated into 
two fractions denoted Ala and Alb which eluted at 30.6% and 
32.4% acetonitrile, respectively. Each fraction was 
rechromatographed using the same conditions and collected 
manually. Similarly, fraction A2 was purified using a linear gra- 
dient (18-45%) of acetonitrile and 0.05% HFBA at 1 ml/min 
for 60 min and yielded two immunoreactive fractions denoted 
A2a and A2b, and eluting at 3 1% and 33% acetonitrile, respec- 
tively. Both fractions were rechromatographed using a linear 
gradient (lo-40%) of acetonitrile and an aqueous phase com- 
posed of 50 mM potassium phosphate and 0.1% triethylamine, 
pH 3.5 (TEAP buffer), at 1 ml/min for 60 min. The fractions 
were then subsequently desalted using a linear gradient 
(15-45%) of acetonitrile and 0.1% TFA at 1 ml/min over a 
period of 30 min. Both fractions A2a and A2b eluted at 25% 
acetonitrile and were manually collected. All purifications were 
followed by monitoring UV-absorbance at 214 nm. 
2.3. Purification of ANF-fraction C 
The fraction C was submitted to a linear gradient (30-60%) 
of acetonitrile and 0.1% TFA at 1 ml/min for 60 min. The 
resulting immunoreactive peak was further purified using a 
linear gradient (15-45%) of isopropanol and TEAP buffer at 
1 ml/min for a period of 60 min. The single ANF-like peak, 
eluting at 34.5% isopropanol, was finally desalted using a linear 
gradient (20-50%) of acetonitrile and 0.1% TFA at 1 ml/min 
in 30 min. 
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2.4. ANF detection procedures 
The ANF content of all HPLC-derived fractions was con- 
stantly monitored using two previously described procedures. 
The first one relies on RIA using a rabbit antiserum developed 
against rat ANF (99-126) coupled to bovine serum albumin us- 
ing a soluble carbodiimide; cross-reactivity of this antiserum 
with synthetic ANF sequences (atriopeptin I, II, III and rat 
ANF (101-126)) was greater than 90% 1121. The second one 
relied on the measurement of ANF-like reactivity using RRA as 
previously described [ 131. Both assays detect the biologically ac- 
tive and circulating form of ANF (99-126) but the cross- 
reactivity of the precursor form (l-126) in the RRA is only 
5-10% of that obtained with RIA. 
2.5. Amino acid and sequence analysis 
The HPLC-purified peptides were hydrolyzed in their native 
or performic acid oxidized state in vacua using 5.7 N HCI at 
1IOOC for 24 h. The amino acids were separated and quan- 
titated on a modified Beckman 12OC autoanalyser equipped 
with a Variant DS604 plotter/integrator; detection was carried 
out using post-column ninhydrin. 
The amino acid sequence determination was carried out on 
two automatic sequenators. The liquid-phase Beckman 890M 
and the gas-phase Applied Biosystem model 470A sequenators 
were operated as described [14]. The released thiazolinones, 
after conversion into PTH-derivatives, were separated and 
quantitated by HPLC as described [15]. 
3. RESULTS 
In order to gain some insight on the behavior of 
ANF-like molecules in frog atria, a down scaled 
isolation scheme was attempted. Enough material 
was obtained so that an amino acid composition of 
the reduced and carboxymethylated ANF-like pep- 
tide and a partial amino acid sequence was possi- 
ble. Both preliminary results confirmed the high 
degree of relatedness of the frog material to mam- 
malian ANF. Indeed, the amino acid composition 
as revealed by the following molar ratio Asx (2.3), 
Ser (4.5), Glx (1.6), Gly (9.0), Ala (2.0), Met (1.4), 
Ile (1.7), Phe (1.8), Arg (5.7) and CM-Cys (1.9) is 
remarkably close to the known one of mammalian 
ANF (99-126); one should note the absence of 
Leu, Lys, His, Thr and especially Tyr residues. 
The amino acid sequence determination using the 
liquid-phase sequenator allowed the identification 
of 20 residues out of 30 cycles and indicated the 
similarity of the frog sequence in particular in the 
disulfide loop to its mammalian counterpart (not 
shown). 
Due to the restricted availability of the frog atria 
and the low amount of material, the purification 
of the material obtained from 49 g of tissue was 
accomplished using the following three criteria, (i) 
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Fig. 1. (A) Reverse-phase HPLC chromatogram of acid extracts 
of frog heart atria on semi-preparative PBondapak-Cis column 
with a linear gradient of acetonitrile as indicated by the dashed 
line. Monitoring of the eluate was done by measuring 
absorbance at 280 nm. (B) Monitoring of the eluate using RIA. 
The two activity zones eluting at 28.5% and 44% acetonitrile, 
respectively, were collected and further purified. 
detection by RIA and RRA, (ii) appearance of a 
homogeneous peak on HPLC and (iii) an amino 
acid composition similar to the one obtained 
above. Throughout this study, these criteria were 
applied to all fractions eluting from the various 
columns used. 
The initial separation, folowing the ion- 
exchange step, yielded three major immunoreac- 
tive fractions as shown in fig.1. The elution posi- 
tions were also very close to what has been 
observed under the same conditions while purify- 
ing the ANF and its precursor from bovine adrenal 
medulla [16]. Indeed, the lower molecular mass 
form of ANF was found to elute at 26% 
acetonitrile (compared here to 28.5%) whereas the 
precursor form (ANF 1-126) eluted at 39% (com- 
pared here to 44%). It should be mentioned here 
that actually throughout the later purification 
steps this chromatographic correspondence was 
Volume 238, number 2 FEBS LETTERS October 1988 
{ 
s . . 
8 
S .F 
R 
S 
S 
TIME (minutes) 
60 
!!i 
60 g 
8 
40 q 
w 
20 
1.000 
r 5 
*s F 
S H 
D C 
‘I 
-I /-I/ 
15 20 25 
c 
s 
s 
TIME (minutes) 
60 
2 1.500 u 
s 1 
8 60 E 
3 1.000 5 
cz 40 s 8 
H 
$ 0.500 
20 
0.000 0 
0 10 20 30 40 50 
TIME (minutes) 
s s 
Fig.2. (A, C and E) Reverse-phase HPLC chromatograms representing the last purification step of fraction A2a (A), A2b (C) and 
C (E), respectively. The arrowhead indicates in each case the peak which was manually collected and submitted to amino acid 
sequencing. Detection of the peaks was done by measuring absorbance at 214 nm. (B, D and F) Quantitative yields of PTH-amino 
acid derivatives recovered uring sequence analysis of fraction A2a (B), A2b (D) and C (F) are illustrated as a function of cycle numbers 
after normalizing to a PTH-NorLeucine internal standard. The repetitive and initial yields are determined by the slope and intercept 
obtained by linear regression analysis on selected stable PTH-derivatives. 
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observed. Two of the three fractions were process- 
ed further, the early eluting one (around 45 min, 
fraction A) containing the bulk of ANF im- 
munoreactivity and the late eluting one (around 
74 min, fraction C) which was recognized by RIA 
but minimally if at all by RRA. 
Following numerous chromatographic steps as 
described in section 2.2, four immunoreactive frac- 
tions, albeit displaying low RIA-reactivities at the 
later stage of purification, were isolated and three 
of these, Alb, A2a and A2b, submitted to amino 
acid sequencing. Fraction Alb was found to con- 
tain two sequences which were both identified as (i) 
APRSMRRSSDX- 
FGSRIDRIGAQXGMGXGR(F) for which the in- 
itial and repetitive yields were 115 pmol and 
92.8%, respectively (not shown), and (ii) WIKY- 
QEYDEAGPSIVXXKXF for which the initial and 
repetitive yields were 47 pmol and 91.8%, respec- 
tively (not shown). The latter, upon searching in 
the Protein Data Bank (National Biomedical 
Research Foundation, Washington, proved to be 
very closely related to the COOH-terminal frag- 
ment of mammalian cardiac muscle actin starting 
at position 358 (11 residues out of 14 are identical). 
Fraction A2a, as shown in fig.2A, proved to be 
contaminated up to the last step with a high UV- 
absorbance material eluting before it which could 
not be identified either by composition or by se- 
quence analysis (no PTH-derivatives were ob- 
served). However the fraction marked by an 
arrowhead yielded the sequence shown in fig.2B 
with an initial yield and repetitive yield of 
829 pmol and 90.7%, respectively. Here again 
though, a minor sequence (not shown) was 
detected which corresponded to KVDAHKIG- 
GEALAR (initial and repetitive yields of 274 pmol 
and 95.1%); this sequence proved 100% identical 
to a fragment of frog hemoglobin&chain. Finally, 
fraction A2b despite its apparent homogeneity as 
shown in fig.2C and its yielding a unique sequence 
(initial and repetitive yield of 213 pmol and 
92.8%) as shown in fig.2D failed to give, as 
observed with the other fractions derived from 
pool A, an unambiguous amino acid composition. 
This fact complicated greatly the assignment of the 
COOH-terminal residues. Indeed, during the se- 
quencing of Alb, A2a and especially A2b, the 
presence of Arg at cycle 29 and 30 as well as Phe 
at cycle 30 and 31 rendered very difficult the 
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assignment of an Arg-Phe, an Arg-Arg-Phe or 
even an Arg-Arg-Phe-Phe sequence past the Arg 
occupying position 29. Due to the amino acid com- 
position described previously in the preliminary 
results and also to the sequence similarity (as 
discussed in the following section) between known 
ANF sequences, the COOH-terminal sequence was 
tentatively identified as being Arg-Phe. The 
presence of Arg and Phe in cycle 30 and 31 could 
be explained by high carry-over of the preceding 
cycles which, however, cannot rule out entirely the 
other possibilities. Taking into account the iden- 
tification of the contaminants and of cysteic acid 
upon oxidation and amino acid analysis, it can be 
said that the sequence results agreed with the 
presence of two half-cystine residues (fig.2B, cycle 
11 and 27 and fig.2D, cycle 4 and 20) since these 
residues are not detected with the method used. 
Based upon its chromatographic behavior which 
followed very closely the one previously observed 
for bovine pro-ANF [ 161 and its lack of reactivity 
in the RRA, fraction C was tentatively identified as 
frog pro-ANF. This identification was reinforced 
following final purification, shown in fig.2E, and 
amino acid sequence analysis, shown in fig.2F. 
The deduced amino acid sequence GPVYNSPLS- 
SDLFDL (initial yield and repetitive yield of 
169 pmol and 84%) despite the need to be confirm- 
ed yet again, and the following amino acid com- 
position, Asx (16.9), Thr (3.1), Ser (16.6), Glx 
(12), Pro (7.3), Gly (10.2), Ala (10.7), Val (3.2), 
Met (2.7), Be (1.9), Leu (11.6), Tyr (3.2), Phe 
(3.0), Lys (3.2), Arg (13.2) and Cys (1.9) would be 
in agreement with its identification as frog pro- 
ANF. Indeed, the amino acid composition, where 
His was not detected and Trp not identified, 
predicts a molecule of around 121 residues and 
yields amino acid ratios close to those observed 
with mammalian pro-ANF. 
4. DISCUSSION 
Despite the problems encountered during 
purification (and probably due to protein degrada- 
tion during shipment or extraction), alluded to in 
section 3, and despite the absence of biological 
data apart from its binding to the receptor in the 
RRA, it can be said that, indeed, an amphibian 
form of ANF has been isolated and sequenced. 
As shown in fig.3, the deduced sequence of the 
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Fig.3. Amino acid sequence comparison between frog ANF and previously reported sequences of mammalian ANF taken from (21 
and of BNP Ill]. Identical residues are enclosed inboxes whereas the - sign indicates a gap introduced in order to maximize the identity. 
The numbering at the bottom of the figure refers to the residue numbering in mammalian ANF sequences. The Phe residue occupying 
position 30 was tentitatively assigned (see sections 3 and 4). 
longer form of frog ANF isolated displays a 
significant homology to known mammalian se- 
quences. The whole disulfide bridge, recognized as 
important for expression of biological activity in 
mammals [17] is entirely conserved in both 
systems. Within these positions (1 l-27), only two 
substitutions were observed, both of which 
resulted from single nucleotide substitutions and 
are chemically equivalent; interestingly, the only 
previously reported substitution, the Met/Ile at 
position 16, corresponds here to an Ile residue as 
found in rodent. Other residues thought to be im- 
portant for the biological action are also conserved 
such as those bearing hydrophobic side chains, 
Phe-12, Ile-19 and Met-25 (here, replacing a Leu) 
and those, Gly-20, Gly-24 and Gly-26, which might 
be involved in conformation are retained [18]. On 
the COOH-terminal side, in view of the problems 
mentioned in section 3, the sequence has been ten- 
tatively assigned’ as Gly-Arg-Phe even though no 
unambiguous identification could be made. The 
COOH-terminal sequence thus needs to be recon- 
firmed even though no evidence of the presence of 
the normally encountered Tyr residue or others 
apart from Arg and Phe was obtained during this 
study. The latter observation could prove impor- 
tant since, in mammals, high potency is obtained 
as long as at least one cationic site is kept at either 
termini [18]. Upon maximal alignment of the 
region preceding the disulfide bridge, one can 
readily see that, in frog, a single amino acid residue 
was inserted at position 10 but that the other 
amino acids are well conserved. In particular, the 
cleavage site which appears to be recognized by 
mammalian processing enzymes, the single Arg-98, 
is preserved together with the region surrounding 
it. 
Interestingly, whereas the predominant cir- 
culating ANF form which results from this 
cleavage is ANF 99-126 in mammals [ 191, here 
two frog ANF forms were isolated. The first one, 
isolated both in Ala and A2b, is longer by 7 
residues than the shorter one (A2a); the former 
thus resembles those previously characterized by 
Seidah et al. [20], whereas the latter represents 
those denoted atriopeptin by Currie et al. [21]. 
Thus, whereas one can confidently predict that the 
frog peptides should exhibit ANF bioactivities akin 
to mammalian ANF, it would be hazardous to 
speculate on the exact secreted molecular form of 
the active entity in frogs. 
Finally, the last fraction examined (fraction C) 
could possibly be related to the frog pro-ANF 
molecule considering that its behavior in RIA and 
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RRA and its amino acid composition are in agree- 
ment with what was observed in mammals. Fur- 
thermore, the partial sequence of this fraction 
displays a significant similarity to the mammal’s 
sequence. Indeed, amino acids in the sequence Gly- 
Pro-Val-Tyr-Asn-Ser-Pro-Leu-Ser-Ser-Asp-Leu- 
Phe-Asp-Leu can be found within mammalian se- 
quences; Pro-2, Tyr-4, Asp-l 1, Asp-14 and Leu-12 
all occupy the same positions in all known se- 
quences [2] whereas Val-3 (Met in human), Asn-5 
(Gly in bovine, porcine and canine and Ser in rat 
and mouse), Serd (Ala in human and rodents) 
were also observed. Thus 8 positions out of 14 are 
occupied by amino acid previously observed in 
pro-ANF sequences of mammalian origin. The ex- 
tent of this correspondence will depend on further 
studies presently being carried out. 
All in all, this report demonstrates the close 
similarity between mammalian and frog ANF and 
thus should help in future studies concerning the 
role and structure of ANF in lower species. 
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